Symposium:
19. Biofilms and HAIs: Emerging Technologies and Applications
Thursday, October 8, 2015: 8:30 AM-10:00 AM
Room: 29--ABCD

Learning Objectives:

At the conclusion of this session, participants will be bale to:

  • describe the development of biofilm and emerging technologies to prevent and disrupt biofilms
  • discuss the evidence supporting the effectiveness of antimicrobial catheters, locks and caps in preventing central line-associated blood stream infection
  • evaluate the evidence supporting the effectiveness of antimicrobial-coated sutures in preventing surgical site infection

Target Audience: Members-in-training, Investigators, Infection preventionists, Hospital epidemiologists, Fellows, Epidemiologists

Tracks: Investigative ID, Epidemiology and Infection Control

Moderators:  Leonard Mermel, DO, ScM, FACP, FIDSA, FSHEA, Warren Alpert Medical School of Brown University and Kerry Laplante, PharmD, University of Rhode Island

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 CreditTM

ACPE Credits: No CPE credit is offered for this session

ACPE Number:

Disclosures:

L. Mermel, CareFusion: Consultant , Consulting fee and Research grant
Marvao Medical: Consultant , Consulting fee and Research grant
Bard: Consultant , Consulting fee
Fresenius: Consultant , Consulting fee
3M: Consultant , Consulting fee

K. Laplante, Cubist Pharmaceuticals: Grant Investigator , Scientific Advisor and Speaker's Bureau , Consulting fee , Grant recipient and Speaker honorarium
Pfizer Pharmaceuticals: Grant Investigator , Grant recipient
Theravance Biopharma: Grant Investigator and Scientific Advisor , Consulting fee and Grant recipient
Durata: Scientific Advisor , Consulting fee
Forest Laboratories: Scientific Advisor , Consulting fee
Marvao: Grant Investigator , Grant recipient
Melinta: Scientific Advisor , Consulting fee
Davol: Scientific Advisor , Consulting fee
Theradoc: Scientific Advisor , Consulting fee

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.